Low‑Input 3D Genome Maps Tie Crohn’s Risk Variants to ILC3 Genes

Overview

• The study published Tuesday, August 4, 2026 used an optimized low‑input promoter capture Hi‑C (PCHi‑C) on primary human type 3 innate lymphoid cells (ILC3s) and a Bayesian multiCOGS analysis to assign Crohn’s disease risk variants to likely target genes, prioritizing more than 100 candidates.
• The low‑input PCHi‑C protocol maps promoter‑anchored long‑range DNA contacts in rare tissue‑resident cells using far fewer cells than conventional methods, making high‑resolution 3D maps of ILC3s feasible for the first time.
• CLN3, a gene previously linked to Batten neurodegenerative disease, emerged as an unexpected ILC3 candidate; follow‑up experiments in a mouse ILC3‑like line showed CLN3 falls with cytokine stimulation and that raising CLN3 levels alters inflammatory gene programs and cytokine release, but the data do not prove it causes Crohn’s disease.
• The team applied the same mapping and analysis pipeline to five other autoimmune GWAS and produced an ILC3 risk‑gene catalog that was enriched for regulators flagged in a CRISPR interference screen, helping prioritize genes for functional follow‑up.
• The work creates a platform for moving GWAS signals toward mechanisms by revealing which distant regulatory elements control which genes, and it sets up next steps to test CLN3’s role, validate pathways in human disease, and extend the approach to other rare cell types to guide future drug and biomarker discovery.